Patent · US Active

Anti-podocalyxin antibodies and methods of using the same

US11390673B2 · kind B2 · utility

1Cited by
3References
17Claims
0Family size

Inventors

Key dates

Filing dateAug 12, 2019
Grant dateJul 19, 2022
Priority date
Expiry dateOct 3, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to compositions of matter useful for the treatment of cancer in mammals and to methods of using those compositions of matter for the same. Antibodies specific for podocalyxin designated Ab1 and 3G2 are disclosed, as is the use of said antibodies for the inhibition of growth of a tumor that expresses podocalyxin, and the use of said anti bodies for targeting tumour endothelial cells that express podocalyxin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.